Who
Kurt A. Gustafson
Director
Company insider
Files Form 4 as: Director, Xencor; Executive VP, Finance and CFO, OmniAb; EVP, Finance and CFO, OmniAb Operations; EVP & Chief Financial Officer, Spectrum Pharmaceuticals; Director, Niagen Bioscience; Vice President and CFO, Halozyme Therapeutics.
In numbers
- Trades disclosed
- 171
- Buys
- 2
- Sells
- 41
- Bought
- $75K
- Sold
- $2.1M
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 4 Feb 2010
- Last trade
- 16 Jun 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $67K5,474 at $12.31 | filing |
| 15 Jun 2026filed 17 Jun 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $67K5,474 at $12.31 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —13,542 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $10K6,913 at $1.49 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —13,542 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —13,542 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —13,542 at $0.00 | filing |
| 7 Apr 2026filed 7 Apr 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $10K6,913 at $1.49 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Sold | $16K9,301 at $1.71 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
News
OmniAb (NASDAQ:OABI) Stock Price Target Raised at Leerink PartnersOABI · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Kurt A. Gustafson; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.